Mayfair Advisory Group LLC Has $285,000 Holdings in Pfizer Inc. (NYSE:PFE)

Mayfair Advisory Group LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 4.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,758 shares of the biopharmaceutical company’s stock after purchasing an additional 479 shares during the period. Mayfair Advisory Group LLC’s holdings in Pfizer were worth $285,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Ignite Planners LLC boosted its stake in shares of Pfizer by 11.2% during the 4th quarter. Ignite Planners LLC now owns 37,978 shares of the biopharmaceutical company’s stock worth $1,010,000 after buying an additional 3,834 shares during the last quarter. Wallace Advisory Group LLC raised its holdings in Pfizer by 4.0% during the fourth quarter. Wallace Advisory Group LLC now owns 16,128 shares of the biopharmaceutical company’s stock worth $467,000 after acquiring an additional 616 shares in the last quarter. 180 Wealth Advisors LLC boosted its position in Pfizer by 15.4% during the fourth quarter. 180 Wealth Advisors LLC now owns 36,014 shares of the biopharmaceutical company’s stock valued at $955,000 after purchasing an additional 4,805 shares during the last quarter. Rosenberg Matthew Hamilton grew its stake in Pfizer by 59.9% in the fourth quarter. Rosenberg Matthew Hamilton now owns 2,029 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 760 shares in the last quarter. Finally, Wright Investors Service Inc. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $448,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Stock Down 1.5 %

PFE stock opened at $26.41 on Wednesday. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $149.67 billion, a price-to-earnings ratio of 35.69, a PEG ratio of 0.63 and a beta of 0.64. The business’s fifty day moving average price is $26.13 and its two-hundred day moving average price is $28.03.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.17) earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.51%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s payout ratio is 232.43%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Citigroup assumed coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Wolfe Research began coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock. Finally, Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.